One Nucleus, a membership organisation for life sciences and healthcare companies, has announced the appointment of Linda Summerton as a director.

Summerton is chief executive of Immodulon Therapeutics and a senior partner with TranScrip Partners. She previously worked for 18 years at AstraZeneca, and brings 25 years’ experience in the global pharmaceutical industry.

Chair of One Nucleus Jon Green commented: “Linda is a great addition to the team. She has a deep understanding of the needs of One Nucleus members, and this coupled with her current interests, particularly as CEO of a growing biotech company make her an ideal director for One Nucleus.”

Summerton said: “These are challenging times for life sciences and healthcare companies and One Nucleus is extremely well placed to support the sector. I am delighted to have been asked to join the board and look forward to bringing my experience to the table, to support the team and assist One Nucleus members.”

The Cambridge-based not-for-profit was established in 1997.